



The methyl-CpG-binding domain 2 facilitates pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation

Yi Wang^{1,5}, Lei Zhang^{1,5}, Teng Huang¹, Guo-Rao Wu¹, Qing Zhou ¹, Fa-Xi Wang¹, Long-Min Chen¹, Fei Sun¹, Yongman Lv², Fei Xiong¹, Shu Zhang¹, Qilin Yu¹, Ping Yang¹, Weikuan Gu³, Yongjian Xu¹, Jianping Zhao^{1,6}, Huilan Zhang^{1,6}, Weining Xiong^{1,4,6} and Cong-Yi Wang^{1,6}

¹The Center for Biomedical Research, Dept of Respiratory and Critical Care Medicine, National Health Commission (NHC) Key Laboratory of Respiratory Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. ²Health Management Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. ³Dept of Orthopedic Surgery and BME-Campbell Clinic, University of Tennessee Health Science Center, Memphis, TN, USA. ⁴Dept of Respiratory and Critical Care Medicine, Shanghai Key Laboratory of Tissue Engineering, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. ⁵These authors contributed equally to this work. ⁶Jianping Zhao, Huilan Zhang, Weining Xiong and Cong-Yi Wang contributed equally to this article as lead authors and supervised the work.

Corresponding author: Cong-Yi Wang (wangcy@tjh.tjmu.edu.cn)



Shareable abstract (@ERSpublications)

MBD2 is upregulated in the myofibroblasts from IPF patients and facilitates the transition of myofibroblast from fibroblast via TβRI/Smad3/Mbd2/Erdr1 positive feedback regulatory loop
<https://bit.ly/3q0PhHA>

Cite this article as: Wang Y, Zhang L, Huang T, *et al.* The methyl-CpG-binding domain 2 facilitates pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation. *Eur Respir J* 2022; 60: 2003697 [DOI: 10.1183/13993003.03697-2020].

This single-page version can be shared freely online.

Copyright ©The authors 2022.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

This article has an editorial commentary:
<https://doi.org/10.1183/13993003.01536-2022>

Received: 1 Oct 2020
Accepted: 9 Dec 2021

Abstract

Although DNA methylation has been recognised in the pathogenesis of idiopathic pulmonary fibrosis (IPF), the exact mechanisms are yet to be fully addressed. Herein, we demonstrate that lungs originated from IPF patients and mice after bleomycin (BLM)-induced pulmonary fibrosis are characterised by altered DNA methylation along with overexpression in myofibroblasts of methyl-CpG-binding domain 2 (MBD2), a reader responsible for interpreting DNA methylome-encoded information. Specifically, depletion of *Mbd2* in fibroblasts or myofibroblasts protected mice from BLM-induced pulmonary fibrosis coupled with a significant reduction of fibroblast differentiation. Mechanistically, transforming growth factor (TGF)-β1 induced a positive feedback regulatory loop between TGF-β receptor I (TβRI), Smad3 and Mbd2, and erythroid differentiation regulator 1 (Erdr1). TGF-β1 induced fibroblasts to undergo a global DNA hypermethylation along with Mbd2 overexpression in a TβRI/Smad3 dependent manner, and Mbd2 selectively bound to the methylated CpG DNA within the *Erdr1* promoter to repress its expression, through which it enhanced TGF-β/Smad signalling to promote differentiation of fibroblast into myofibroblast and exacerbate pulmonary fibrosis. Therefore, enhancing Erdr1 expression strikingly reversed established pulmonary fibrosis. Collectively, our data support that strategies aimed at silencing Mbd2 or increasing Erdr1 could be viable therapeutic approaches for prevention and treatment of pulmonary fibrosis in clinical settings.

